HK1218248A1 - 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 - Google Patents

冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 Download PDF

Info

Publication number
HK1218248A1
HK1218248A1 HK16106215.8A HK16106215A HK1218248A1 HK 1218248 A1 HK1218248 A1 HK 1218248A1 HK 16106215 A HK16106215 A HK 16106215A HK 1218248 A1 HK1218248 A1 HK 1218248A1
Authority
HK
Hong Kong
Prior art keywords
peptide
composition
amino acid
agent
peptide agent
Prior art date
Application number
HK16106215.8A
Other languages
English (en)
Chinese (zh)
Inventor
大衛．克羅克福德
大卫．克罗克福德
阿蘭．
阿兰．L.．戈尔茨坦
．戈爾茨坦
Original Assignee
雷金纳克斯生物制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 雷金纳克斯生物制药公司 filed Critical 雷金纳克斯生物制药公司
Publication of HK1218248A1 publication Critical patent/HK1218248A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
HK16106215.8A 2005-06-17 2016-06-01 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 HK1218248A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US60/691,261 2005-06-17
US77694706P 2006-02-28 2006-02-28
US60/776,947 2006-02-28

Publications (1)

Publication Number Publication Date
HK1218248A1 true HK1218248A1 (zh) 2017-02-10

Family

ID=37570786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106215.8A HK1218248A1 (zh) 2005-06-17 2016-06-01 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物

Country Status (11)

Country Link
US (8) US20090131313A1 (https=)
EP (4) EP1896050A4 (https=)
JP (3) JP2008543878A (https=)
KR (3) KR20080033939A (https=)
CN (1) CN105106931A (https=)
AU (3) AU2006261157A1 (https=)
CA (3) CA2612522A1 (https=)
HK (1) HK1218248A1 (https=)
IL (4) IL187522A0 (https=)
MX (3) MX2007015958A (https=)
WO (3) WO2006138709A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718774A1 (en) * 2008-03-17 2009-12-17 Regenerx Biopharmaceuticals, Inc. Improved beta thymosin fragments
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2011044589A2 (en) * 2009-10-09 2011-04-14 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
DK2819682T3 (en) 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
AU2014345802B2 (en) * 2013-11-07 2018-01-25 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Storage stable lyophilized tripeptide formulations
CA2942035A1 (en) 2014-03-12 2015-09-17 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease
WO2016064078A1 (ko) 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US9867868B2 (en) 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
JP6996713B2 (ja) * 2015-10-06 2022-02-04 エイチエルビー・セラピューティクス・カンパニー・リミテッド チモシンベータ４を含む眼科用製剤の製造方法
CA3031069A1 (en) * 2016-07-18 2018-01-25 Regentree, Llc Methods of treating dry eye syndrome
KR102115158B1 (ko) 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
KR20250023579A (ko) * 2017-02-21 2025-02-18 티얼솔루션즈, 인크. 안정한 펩타이드 조성물
KR102340750B1 (ko) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
CN111386337A (zh) * 2017-11-24 2020-07-07 Gtreebnt科技有限公司 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
WO2024006653A2 (en) * 2022-07-01 2024-01-04 Tearsolutions, Inc. Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
EP1591128A1 (en) * 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2005502672A (ja) * 2001-08-29 2005-01-27 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
CA2497977A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
EP1613369A4 (en) * 2003-03-31 2008-10-01 Regenerx Biopharmaceuticals COMPOSITIONS AND METHODS OF DELIVERING THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
CN108738377B (zh) 2015-07-30 2020-11-10 株式会社半导体能源研究所 发光装置的制造方法、发光装置、模块及电子设备

Also Published As

Publication number Publication date
US20090131313A1 (en) 2009-05-21
AU2006261157A1 (en) 2006-12-28
CA2612410A1 (en) 2006-12-28
WO2006138708A1 (en) 2006-12-28
WO2006138709A2 (en) 2006-12-28
IL218504A (en) 2013-10-31
US20170128540A1 (en) 2017-05-11
JP2008543878A (ja) 2008-12-04
JP2008543879A (ja) 2008-12-04
MX2007015958A (es) 2008-04-17
US20120071411A1 (en) 2012-03-22
US20090118196A1 (en) 2009-05-07
IL218504A0 (en) 2012-04-30
IL187781A0 (en) 2008-08-07
IL187522A0 (en) 2008-03-20
US20160193301A1 (en) 2016-07-07
AU2006261155A1 (en) 2006-12-28
US9821030B2 (en) 2017-11-21
CA2612405A1 (en) 2006-12-28
KR20080021782A (ko) 2008-03-07
MX2007015956A (es) 2008-03-06
US20180028619A1 (en) 2018-02-01
IL187617A0 (en) 2008-03-20
EP1896050A2 (en) 2008-03-12
EP1906986A1 (en) 2008-04-09
KR20080033939A (ko) 2008-04-17
US9585941B2 (en) 2017-03-07
EP1904080A1 (en) 2008-04-02
US8383576B2 (en) 2013-02-26
US20160287673A1 (en) 2016-10-06
CN105106931A (zh) 2015-12-02
JP2008543877A (ja) 2008-12-04
WO2006138708B1 (en) 2007-04-05
EP1896050A4 (en) 2010-01-27
US10004785B2 (en) 2018-06-26
WO2006138709A3 (en) 2007-07-05
IL187781A (en) 2012-04-30
WO2006138707A1 (en) 2006-12-28
AU2006261156A1 (en) 2006-12-28
EP1906986A4 (en) 2011-02-23
EP3326647A1 (en) 2018-05-30
AU2006261156B2 (en) 2012-05-31
CA2612522A1 (en) 2006-12-28
US20080214456A1 (en) 2008-09-04
KR20080018268A (ko) 2008-02-27
MX2007015957A (es) 2008-03-06
EP1904080A4 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
US10004785B2 (en) LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
ZA200503975B (en) Use of rimexolone in the treatment of dry eye
WO2008108927A2 (en) Methods and compositions for stabilizing polypeptides
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
JP2023530188A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
CN101198346A (zh) Lkktet和/或lkktnt肽组合物及方法
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized
US20230158045A1 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
CN119730839A (zh) 稳定的肽组合物及使用其治疗中/重度干眼相关的眼部症状的方法